Journal article
Hydroxyurea induced acute elevations in liver function tests
Journal of oncology pharmacy practice, Vol.14(1), pp.61-63
03/2008
DOI: 10.1177/1078155207086814
PMID: 18337443
Abstract
Hydroxyurea (HU) is a ribonucleotide reductase inhibitor used to treat myeloproliferative diseases including polycythemia vera (PV) and essential thrombocythemia (ET). We describe an 82-year-old male who was started on HU 500 mg three times weekly for the treatment of PV. Eight days after initiation of HU he experienced anorexia, nausea, vomiting, fever, fatigue, dizziness, and shaking chills. Discontinuation of the HU resulted in resolution of his symptoms within 2 days, and HU was re-started. Ten days after re-starting HU, the patient re-presented with nausea and anorexia. Lab tests revealed elevations in liver enzyme function tests, which resolved promptly after cessation of HU. Patients being initiated on HU should be advised that rarely, fevers, chills, nausea, and elevations in liver function tests may occur.
Details
- Title: Subtitle
- Hydroxyurea induced acute elevations in liver function tests
- Creators
- Mike J Hallam - University of Wisconsin–MadisonJill M Kolesar - University of Wisconsin–Madison
- Resource Type
- Journal article
- Publication Details
- Journal of oncology pharmacy practice, Vol.14(1), pp.61-63
- DOI
- 10.1177/1078155207086814
- PMID
- 18337443
- ISSN
- 1078-1552
- eISSN
- 1477-092X
- Language
- English
- Date published
- 03/2008
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9984696546102771
Metrics
5 Record Views